Status:
TERMINATED
18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
Lead Sponsor:
Davidzon, Guido, M.D.
Conditions:
Osteosarcoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patien...
Detailed Description
Primary Objective: Demonstrate correlation of pre-post reduction in 18F-FTC-146 PET/CT with amount of post-treatment tumor necrosis in newly-diagnosed and treated osteosarcoma patients. Secondary Obj...
Eligibility Criteria
Inclusion
- Patients with biopsy proven osteosarcoma requiring local surgical intervention.
- ECOG ≤ 2
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Chemotherapy in the past 2 months.
- Prior history of allergic reaction to 18F FTC 146.
- Pregnant or nursing
Key Trial Info
Start Date :
January 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 22 2021
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04365660
Start Date
January 28 2021
End Date
July 22 2021
Last Update
November 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94304